Comparison of Nodal Staging in Endometrial Cancer

Launched by FREDERICK R. UELAND, M.D. · Jul 9, 2021

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy
• • Histologically or cytologically confirmed endometrioid-type endometrial cancer confined to the uterine corpus
• • No clinical evidence of extra-uterine disease on pre-operative evaluation.
• • Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.
• • Age ≥18 years.
• • Life expectancy (estimated survival) of at least 6 months.
• • AST(SGOT)/ALT(SGPT) \< 3.0X upper limit of normal
• • Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • GOG/ECOG Performance Status greater than 2
• • Non-endometrioid cell type
• • Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam
• • Previous vaginal, pelvic or abdominal irradiation
• • Chemotherapy, hormone therapy or immunotherapy directed at the present disease
• • Previous pelvic lymphadenectomy or retroperitoneal surgery
• • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
• • Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition
• • Patients with uncontrolled intercurrent illness
• • Patients with psychiatric illness/social situations that would limit compliance with study requirements
• • Pregnant or lactating women